Efficacy of Telmisartan Plus Amlodipine in Nonresponders to CCB Monotherapy

Table 1

Details of trials identified for inclusion into the analysis.

Trial	Description	Patient numbers	Study duration (weeks)	Run-in treatment (weeks)	Randomized treatments (8 weeks)
NCT00558428; Neldam et al. 2011 [20]	A5 nonresponder trial (TEAMSTA-5)	1057	8	A5 (6)	A5, A10, T40/A5, T80/A5
NCT00558064; Boehringer Ingelheim data on file [26]	T40/A5 in A5 nonresponder trial	520	8	A5 (6)	A5, T40/A5
NCT01103960; Boehringer Ingelheim data on file [27]	T80/A5 in A5 nonresponder trial	314	8	A5 (6)	A5, T80/A5
NCT00553267; Neldam et al. 2011 [25]	A10 nonresponder trial (TEAMSTA-10)	921	8	A5 (2), A10 (6)	A10, T40/A10, T80/A10

A5: amlodipine 5 mg; A10: amlodipine 10 mg; T40: telmisartan 40 mg; T80: telmisartan 80 mg; TEAMSTA-5: telmisartan/amlodipine single-pill study to assess the efficacy in patients with essential hypertension not controlled on A5; TEAMSTA-10: telmisartan/amlodipine single-pill study to assess the efficacy in patients with essential hypertension not controlled on A10.